Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea

Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea

Abstract Background Insurance reimbursement provisions in South Korea limit osteoporosis medication availability for patients with T-scores exceeding − 2.5. This study aimed to evaluate the financial impact and fracture prevention of continuous denosumab therapy until a T-score>-2.0 (Dmab-C strat...

Full description

Bibliographic Details
Main Authors: Seungju Cha, Minjeong Sohn, Hyowon Yang, Eric J. Yeh, Ki-Hyun Baek, Jeonghoon Ha, Hyemin Ku
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Musculoskeletal Disorders
Subjects:
Osteoporosis
Denosumab
Osteoporotic fracture
Bone density
Cost-consequence analysis, Republic of Korea
Online Access:https://doi.org/10.1186/s12891-024-07185-8

Internet

https://doi.org/10.1186/s12891-024-07185-8

Similar Items